Prophylaxis Against Venous Thromboembolism in ICU Patients with COVID-19

In a randomized, intensive care unit trial, intermediate-dose enoxaparin was not better than standard-dose enoxaparin.

Observational data have not yet clarified whether patients with COVID-19 benefit from higher-than-standard–dose prophylaxis for venous thromboembolism (VTE; NEJM JW Gen Med Mar 15 2021 and Thromb Haemost 2021; 121:76). Also, patients with COVID-19 in the intensive care unit (ICU) are more likely to die if major bleeding occurs (NEJM JW Oncol Hematol Feb 2021). Investigators randomized 600 ICU patients (median age, 62) with COVID-19 at 10 Iranian academic medical centers to receive either intermediate-dose (enoxaparin, 1 mg/kg daily) or standard-dose (enoxaparin, 40 mg daily) prophylaxis.

The primary efficacy outcome (i.e., 30-day incidence of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or death) occurre…

Reviewing Author

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Prophylaxis Against Venous Thromboembolism in ICU Patients with COVID-19

Topics

Reviewing Author